Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Chemotherapy in Ph+ ALL and Treatment Intensification in High-risk Ph- ALL
NCT00458848Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2004
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of imatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by GIMEMA. Primary endpoint: Disease Free Survival at 60 months. Started Oct 2004; status: completed.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00458848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458848.